Cargando…

Diacylated Sulfoglycolipids Are Novel Mycobacterial Antigens Stimulating CD1-restricted T Cells during Infection with Mycobacterium tuberculosis

Mycobacterial lipids comprise a heterogeneous group of molecules capable of inducing T cell responses in humans. To identify novel antigenic lipids and increase our understanding of lipid-mediated immune responses, we established a panel of T cell clones with different lipid specificities. Using thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilleron, Martine, Stenger, Steffen, Mazorra, Zaima, Wittke, Frederick, Mariotti, Sabrina, Böhmer, Gabriele, Prandi, Jacques, Mori, Lucia, Puzo, Germain, De Libero, Gennaro
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213295/
https://www.ncbi.nlm.nih.gov/pubmed/14981115
http://dx.doi.org/10.1084/jem.20031097
Descripción
Sumario:Mycobacterial lipids comprise a heterogeneous group of molecules capable of inducing T cell responses in humans. To identify novel antigenic lipids and increase our understanding of lipid-mediated immune responses, we established a panel of T cell clones with different lipid specificities. Using this approach we characterized a novel lipid antigen belonging to the group of diacylated sulfoglycolipids purified from Mycobacterium tuberculosis. The structure of this sulfoglycolipid was identified as 2-palmitoyl or 2-stearoyl-3-hydroxyphthioceranoyl-2′-sulfate-α-α′-d-trehalose (Ac(2)SGL). Its immunogenicity is dependent on the presence of the sulfate group and of the two fatty acids. Ac(2)SGL is mainly presented by CD1b molecules after internalization in a cellular compartment with low pH. Ac(2)SGL-specific T cells release interferon γ, efficiently recognize M. tuberculosis–infected cells, and kill intracellular bacteria. The presence of Ac(2)SGL-responsive T cells in vivo is strictly dependent on previous contact with M. tuberculosis, but independent from the development of clinically overt disease. These properties identify Ac(2)SGL as a promising candidate to be tested in novel vaccines against tuberculosis.